Cargando…
Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results
Autores principales: | Aggarwal, Charu, Cohen, Roger, Morrow, Matthew P, Bauml, Joshua, Weinstein, Gregory, Boyer, Jean, Shen, Xuefei, Yan, Jian, Goldenberg, Jessica, Nashit, Drishty, Oyola, Sandra, Lee, Jessica, Humeau, Laurent M, Weiner, David B, Yang, Zane, Bagarazzi, Mark L, Weiner, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652471/ http://dx.doi.org/10.1186/2051-1426-3-S2-P426 |
Ejemplares similares
-
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
por: Morrow, Matthew P, et al.
Publicado: (2016) -
Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL
por: Bhuyan, Prakash K., et al.
Publicado: (2020) -
DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial
por: Humeau, Laurent, et al.
Publicado: (2014) -
Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population
por: Hollenberg, Rebecca K., et al.
Publicado: (2019) -
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors
por: Vonderheide, Robert H, et al.
Publicado: (2021)